877384-16-2

Basic information

• Product Name: benzyl (1R,2S)-1-(3,5-bis(trifluoromethyl)phenyl)-1-hydroxypropan-2-ylcarbamate
• Synonyms: benzyl (1R,2S)-1-(3,5-bis(trifluoromethyl)phenyl)-1-hydroxypropan-2-ylcarbamate;benzyl (1R,2S)-1-(3,5-bis(trifluoroMethyl)phenyl)-1-hydroxypropa;[(1S,2R)-2-[3,5-Bis(trifluoromethyl)phenyl]-2-hydroxy-1-methylethyl]carbamic acid phenylmethyl ester;CarbaMic acid, [(1S,2R)-2-[3,5-bis(trifluoroMethyl)phenyl]-2-hydroxy-1-Methylethyl]-, phenylMethyl ester (9CI);Anacetrapib Intermediate 1
• CAS NO: 877384-16-2
• Molecular Formula: C₁₉H₁₇F₆NO₃
• Molecular Weight: 421
• Product Categories: MK 0859;Anacetrapib
• Mol File: 877384-16-2.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• Density: 1.357
• CAS DataBase Reference: benzyl (1R,2S)-1-(3,5-bis(trifluoromethyl)phenyl)-1-hydroxypropan-2-ylcarbamate(CAS DataBase Reference)
• NIST Chemistry Reference: benzyl (1R,2S)-1-(3,5-bis(trifluoromethyl)phenyl)-1-hydroxypropan-2-ylcarbamate(877384-16-2)
• EPA Substance Registry System: benzyl (1R,2S)-1-(3,5-bis(trifluoromethyl)phenyl)-1-hydroxypropan-2-ylcarbamate(877384-16-2)

Safety Data

• Hazardous Substances Data: 877384-16-2(Hazardous Substances Data)

Usage

General Description

Benzyl (1R,2S)-1-(3,5-bis(trifluoromethyl)phenyl)-1-hydroxypropan-2-ylcarbamate is a chemical compound with a complex structure. It is a carbamate derivative that contains a benzyl group, a hydroxypropan-2-ylcarbamate moiety, and a 3,5-bis(trifluoromethyl)phenyl group. The compound is stereochemically defined as (1R,2S), indicating the specific spatial arrangement of its constituent atoms. This chemical is often used in medicinal chemistry and pharmaceutical research, where its properties contribute to various drug development efforts and synthetic studies. The combination of a benzyl group, a hydroxypropan-2-ylcarbamate, and a 3,5-bis(trifluoromethyl)phenyl group gives this compound a range of potential applications in drug design and synthesis.

Upstream product

• 328-70-1 3,6-bis(trifluoromethyl)bromobenzene 
• 114744-83-1 (S)-benzyl (1-(N,O-dimethylhydroxylamine)-1-oxopropan-2-yl)carbamate 
• 871917-79-2 benzyl {(1S)-2-[3,5-bis(trifluoromethyl)phenyl]-1-methyl-2-oxoethyl}carbamate 

Downstream Products

• 875444-08-9 (4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-4-methyl-1,3-oxazolidin-2-one 
• 1220703-07-0 (1R,2S)-1-[3,5-bis(trifluoromethyl)phenyl]-2-[({2-[4-fluoro-2-methoxy-5-(propan-2-yl)phenyl]-5-(trifluoromethyl)phenyl}methyl)amino]propan-1-ol 
• 875446-37-0 anacetrapib 
• 1620289-77-1 (1R,2S)-1-[3,5-bis(trifluoromethyl)phenyl]-2-[(E)-({2-[4-fluoro-2-methoxy-5-(propan-2-yl)phenyl]-5-(trifluoromethyl)phenyl}methylidene)amino]propan-1-ol 
• 1152029-16-7 (1R,2S)-2-amino-1-[3,5-bis(trifluoromethyl)phenyl]propan-1-ol 

Relevant articles and documents

Chiral purification method of drug intermediate

The invention provides a chiral purification method of a drug intermediate. The chiral purification method of the drug intermediate comprises the following steps: (1) adding a low-optical-purity compound as shown in a formula A4 into a solvent A, carrying

NOVEL OXAZOLIDINONE DERIVATIVE AS CETP INHIBITOR, ITS PREPARATION METHOD, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME

Disclosed are a novel oxazolidinone derivative exhibiting inhibitory activity against CETP, a preparation method thereof, and a pharmaceutical composition comprising the same. Exhibiting excellent inhibitory activity against CETP, the oxazolidinone deriva

Biphenyl-substituted oxazolidinones as cholesteryl ester transfer protein inhibitors: Modifications of the oxazolidinone ring leading to the discovery of anacetrapib

The development of the structure-activity studies leading to the discovery of anacetrapib is described. These studies focused on varying the substitution of the oxazolidinone ring of the 5-aryloxazolidinone system. Specifically, it was found that substitution of the 4-position with a methyl group with the cis-stereochemistry relative to the 5-aryl group afforded compounds with increased cholesteryl ester transfer protein (CETP) inhibition potency and a robust in vivo effect on increasing HDL-C levels in transgenic mice expressing cynomolgus monkey CETP.